Vivani Medical
Suletud
1.15 -1.71
Ülevaade
Aktsiahinna muutus
24h
Min
1.15
Max
1.17
Sissetulek | -103K -6.6M |
|---|---|
Töötajad | 42 |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +220.51% upside |
Järgmine tulemuste avaldamine | 18. mai 2026 |
|---|
Turukapital | 6.5M 79M |
|---|---|
Eelmine avamishind | 2.86 |
Eelmine sulgemishind | 1.15 |
Vivani Medical Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Vivani Medical Prognoos
Hinnasiht
By TipRanks
220.51% tõus
12 kuu keskmine prognoos
Keskmine 3.75 USD 220.51%
Kõrge 4 USD
Madal 3.5 USD
Põhineb 2 Wall Streeti analüütiku instrumendi Vivani Medical 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Maksueelne kasum
Müük
Ärikasum
$
Ettevõttest Vivani Medical
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
